RJRoger A. Johns

Roger A. Johns

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roger A. Johns has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel J. Angelini

    Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine , Baltimore, MD 21205

    1 shared publication
  • Estelle B. Gauda

    Department of Pediatrics, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    1 shared publication
  • Feng Tao

    Department of Biomedical Sciences, Texas A&M University College of Dentistry, Dallas, TX, USA

    1 shared publication
  • Kazuyo Yamaji-Kegan

    Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine , Baltimore, MD 21205

    1 shared publication
  • Myron Yaster

    Professor, Anesthesiology and Critical Care Medicine & Pediatrics, Johns Hopkins University School of Medicine, Charlotte R. Bloomberg Children’s Center, 1800 Orleans Street, Suite 6320, Baltimore, MD 21287, Phone: 410-955-7610/Fax: 410-614-7509

    1 shared publication
  • Qingning Su

    Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine , Baltimore, MD 21205

    1 shared publication

Latest Publications

  • Open Access

    IL-4 Is Proangiogenic in the Lung under Hypoxic Conditions

    by Kazuyo Yamaji-Kegan, Qingning Su, Daniel J. Angelini, Roger A Johns

    IL-4-mediated proangiogenic and proinflammatory vascular responses have been implicated in the pathogenesis of chronic lung diseases such as asthma. Although it is well known that hypoxia induces pulmonary angiogenesis and vascular alterations, the underlying mechanism of IL-4 on the pulmonary vasculature under hypoxic conditions remains unknown. In this context, we designed the present study to determine the functional importance of IL-4 for pulmonary angiogenesis under hypoxic conditions using IL-4 knockout (KO) animals. Our results show that hypoxia significantly increased IL-4Rα expression in wild-type (WT) control lungs. Even though hypoxia significantly up-regulated vascular endothelial growth factor (VEGF) receptor expression in the lungs of both genotypes, hypoxia-induced VEGF, VCAM-1, HIF-1α, and ERK phosphorylation were significantly diminished in IL-4 KO lungs as compared with WT control lungs. In addition, hypoxia-induced pulmonary angiogenesis and proliferating activities in the airway and pulmonary artery were significantly suppressed in IL-4 KO lungs as compared with WT control lungs. We also isolated primary lung fibroblasts from these genotypes and stimulated these cells with hypoxia. Hypoxia-induced VEGF production was significantly suppressed in lung fibroblasts from IL-4 KO mice. These in vitro results are in accordance with the in vivo data. Furthermore, we observed a significant increase of hypoxia-induced pulmonary angiogenesis in STAT6 KO mice similar to that in WT controls. In conclusion, IL-4 has proangiogenic properties in the lung under hypoxic conditions via the VEGF pathway, and this is independent of the STAT6 pathway.


  • Open Access

    Effect of Disrupting N -Methyl-d-aspartate Receptor–Postsynaptic Density Protein-95 Interactions on the Threshold for Halothane Anesthesia in Mice

    by Feng Tao, Roger A. Johns

    Background: The authors' previous studies have shown that clinically relevant concentrations of inhalational anesthetics dose-dependently and specifically inhibit the PSD-95, Dlg, and ZO-1 (PDZ) domain-mediated protein interactions between postsynaptic density protein 95 (PSD-95) and N-methyl-d-aspartate receptors, and that the knockdown of spinal PSD-95 by intrathecal injection of PSD-95 antisense oligodeoxynucleotide significantly reduces the minimum alveolar anesthetic concentration for isoflurane in rats. Methods: The authors constructed a fusion peptide, Tat-PSD-95 PDZ2, comprising the second PDZ domain of PSD-95, which can specifically disrupt PSD-95 PDZ2-mediated protein interactions by binding to its interaction partner. By intraperitoneal injection of this fusion peptide into mice, the authors investigated the effect of disrupting the PSD-95 PDZ2-mediated protein interactions on the threshold for halothane anesthesia. Results: Systemically injected fusion peptide Tat-PSD-95 PDZ2 was delivered into the central nervous system, disrupted the protein-protein interactions between N-methyl-d-aspartate receptor NR2 subunits and PSD-95, and significantly reduced the minimum alveolar anesthetic concentration and righting reflex EC50 for halothane. Conclusions: By disrupting PSD-95 PDZ2 domain-mediated protein interactions, intraperitoneal injection of cell-permeant fusion peptide Tat-PSD-95 PDZ2 dose-dependently reduces the threshold for halothane anesthesia. These results suggest that PDZ domain-mediated protein interactions at synapses in the central nervous system might play an important role in the molecular mechanisms of halothane anesthesia.


  • Open Access

    Distinct Expression of Synaptic NR2A and NR2B in the Central Nervous System and Impaired Morphine Tolerance and Physical Dependence in Mice Deficient in Postsynaptic Density-93 Protein

    by Wen-Jinn Liaw, Xu-Guang Zhu, Myron Yaster, Roger A Johns, Estelle B Gauda, Yuan-Xiang Tao

    Postsynaptic density (PSD)-93, a neuronal scaffolding protein, binds to and clusters N-methyl-D-aspartate receptor (NMDAR) subunits NR2A and NR2B at cellular membranes in vitro. However, the roles of PSD-93 in synaptic NR2A and NR2B targeting in the central nervous system and NMDAR-dependent physiologic and pathologic processes are still unclear. We report here that PSD-93 deficiency significantly decreased the amount of NR2A and NR2B in the synaptosomal membrane fractions derived from spinal cord dorsal horn and forebrain cortex but did not change their levels in the total soluble fraction from either region. However, PSD-93 deficiency did not markedly change the amounts of NR2A and NR2B in either synaptosomal or total soluble fractions from cerebellum. In mice deficient in PSD-93, morphine dose-dependent curve failed to shift significantly rightward as it did in wild type (WT) mice after acute and chronic morphine challenge. Unlike WT mice, PSD-93 knockout mice also showed marked losses of NMDAR-dependent morphine analgesic tolerance and associated abnormal sensitivity in response to mechanical, noxious thermal, and formalin-induced inflammatory stimuli after repeated morphine injection. In addition, PSD-93 knockout mice displayed dramatic loss of jumping activity, a typical NMDAR-mediated morphine withdrawal abstinence behavior. These findings indicate that impaired NMDAR-dependent neuronal plasticity following repeated morphine injection in PSD-93 knockout mice is attributed to PSD-93 deletion-induced alterations of synaptic NR2A and NR2B expression in dorsal horn and forebrain cortex neurons. The selective effect of PSD-93 deletion on synaptic NMDAR expression in these two major pain-related regions might provide the better strategies for the prevention and treatment of opioid tolerance and physical dependence.